Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

Diabetes, use of antidiabetic drugs, and the risk of glioma
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 3418781
Author(s) Seliger, Corinna; Ricci, Cristian; Meier, Christoph R.; Bodmer, Michael; Jick, Susan S.; Bogdahn, Ulrich; Hau, Peter; Leitzmann, Michael F.
Author(s) at UniBasel Bodmer, Michael
Meier, Christian
Meier, Christoph R.
Year 2016
Title Diabetes, use of antidiabetic drugs, and the risk of glioma
Journal Neuro-Oncology
Volume 18
Number 3
Pages / Article-Number 340-9
Abstract Prior epidemiologic studies suggest inverse relations between diabetes and glioma risk, but the underlying mechanisms, including use of antidiabetic drugs, are unknown.; We therefore performed a matched case-control analysis using the Clinical Practice Research Datalink (CPRD). We identified incident glioma cases diagnosed between 1995 and 2012 and matched each case with 10 controls on age, gender, calendar time, general practice, and years of active history in the CPRD. We performed conditional logistic regression to estimate odds ratios (ORs) with 95% CIs, adjusted for body mass index and smoking.; We identified 2005 cases and 20 050 controls. Diabetes was associated with decreased risk of glioma (OR = 0.74; 95% CI = 0.60-0.93), particularly glioblastoma (OR = 0.69; 95% CI = 0.51-0.94). Glioblastoma risk reduction was markedly pronounced among diabetic men (OR = 0.60; 95% CI = 0.40-0.90), most apparently for those with diabetes of long-term duration (OR for >5 vs 0 y = 0.46; 95% CI = 0.26-0.82) or poor glycemic control (OR for HbA1c ≥8 vs <6.5% = 0.20; 95% CI = 0.06-0.70). In contrast, the effect of diabetes on glioblastoma risk was absent among women (OR = 0.85; 95% CI = 0.53-1.36). No significant associations with glioma were found for use of metformin (OR for ≥30 vs 0 prescriptions = 0.72; 95% CI = 0.38-1.39), sulfonylureas (OR = 0.71; 95% CI = 0.39-1.30), or insulin (OR = 0.79; 95% CI = 0.37-1.69).; Antidiabetic treatment appears to be unrelated to glioma, but long-term diabetes duration and increased HbA1c both show decreased glioma risk. Stronger findings in men than women suggest low androgen levels concurrent with diabetes as a biologic mechanism.
Publisher Oxford University Press
ISSN/ISBN 1522-8517 ; 1523-5866
Full Text on edoc Restricted
Digital Object Identifier DOI 10.1093/neuonc/nov100
PubMed ID
ISI-Number WOS:000371597700006
Document type (ISI) Journal Article

MCSS v5.8 PRO. 0.318 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |